Literature DB >> 22796540

Role of matrix Gla protein in angiotensin II-induced exacerbation of vascular calcification.

Guanghong Jia1, Ryan M Stormont, Deepak M Gangahar, Devendra K Agrawal.   

Abstract

Vascular calcification predicts an increased risk for cardiovascular events in atherosclerosis, diabetes, and end-stage kidney diseases. Matrix Gla protein (MGP), an inhibitor of calcification, limits calcium phosphate deposition in the vessel wall. There are many factors contributing to the progression of atherosclerosis, including hypertension, hyperlipidemia, the renin-angiotensin system, and inflammation. Angiotensin II (ANG II) plays a crucial role in the atherogenic process through not only its pressor responses but also its growth-promoting and inflammatory effects. In this study, we investigated the role of MGP in ANG II-induced exacerbation of vascular calcification in human vascular smooth muscle cells (VSMCs). The expression of MGP, calcification, and apoptosis in human VSMCs were examined by Western blot analysis, real-time PCR, in situ terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling, and enzyme-linked immunosorbent assay, respectively. Increase in VSMC calcification in human atherosclerotic plaques upregulates MGP expression and apoptosis in a negative feedback manner. ANG II inhibited MGP expression in VSMCs via and in vitro in a dose- and time-dependent manner through ANG II type 1 receptor and NF-κB signaling pathway. Meanwhile, MGP inhibited the calcification, caspase-3 activity, activation of runt-related transcription factor 2, and release of inflammatory cytokines by VSMCs induced by calcification medium (2.5 mM P(i)) and ANG II in vitro. These observations provide evidence that ANG II exacerbates vascular calcification through activation of the transcription factors, runt-related transcription factor 2 and NF-κB, and regulation of MGP, inflammatory cytokines expression in human VSMCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22796540      PMCID: PMC3468471          DOI: 10.1152/ajpheart.00826.2011

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  24 in total

Review 1.  Molecular mechanisms mediating vascular calcification: role of matrix Gla protein.

Authors:  Diane Proudfoot; Catherine M Shanahan
Journal:  Nephrology (Carlton)       Date:  2006-10       Impact factor: 2.506

2.  Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification.

Authors:  Joanne L Reynolds; Jeremy N Skepper; Rosamund McNair; Takeshi Kasama; Kunal Gupta; Peter L Weissberg; Willi Jahnen-Dechent; Catherine M Shanahan
Journal:  J Am Soc Nephrol       Date:  2005-08-10       Impact factor: 10.121

Review 3.  Vascular calcification: pathobiological mechanisms and clinical implications.

Authors:  Rebecca C Johnson; Jane A Leopold; Joseph Loscalzo
Journal:  Circ Res       Date:  2006-11-10       Impact factor: 17.367

4.  Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells.

Authors:  Walkyria O Sampaio; Carlos Henrique de Castro; Robson A S Santos; Ernesto L Schiffrin; Rhian M Touyz
Journal:  Hypertension       Date:  2007-11-05       Impact factor: 10.190

5.  Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK.

Authors:  Takahisa Tanikawa; Yosuke Okada; Rena Tanikawa; Yoshiya Tanaka
Journal:  J Vasc Res       Date:  2009-06-30       Impact factor: 1.934

6.  Irbesartan attenuates Ang II-induced BMP-2 expression in human umbilical vein endothelial cells.

Authors:  Ming Zhang; Sheng-hua Zhou; Shui-Ping Zhao; Qi-ming Liu; Xu-ping Li; Xiang-Qian Shen
Journal:  Vasc Med       Date:  2008-08       Impact factor: 3.239

7.  Involvement of connexin 43 in angiotensin II-induced migration and proliferation of saphenous vein smooth muscle cells via the MAPK-AP-1 signaling pathway.

Authors:  Guanghong Jia; Gang Cheng; Deepak M Gangahar; Devendra K Agrawal
Journal:  J Mol Cell Cardiol       Date:  2008-03-12       Impact factor: 5.000

8.  Upregulation of cardiac matrix Gla protein expression in response to hypertrophic stimuli.

Authors:  Erja Mustonen; Virva Pohjolainen; Jani Aro; Sampsa Pikkarainen; Hanna Leskinen; Heikki Ruskoaho; Jaana Rysä
Journal:  Blood Press       Date:  2009       Impact factor: 2.835

9.  Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries.

Authors:  Mei Y Speer; Hsueh-Ying Yang; Thea Brabb; Elizabeth Leaf; Amy Look; Wei-Ling Lin; Andrew Frutkin; David Dichek; Cecilia M Giachelli
Journal:  Circ Res       Date:  2009-02-05       Impact factor: 17.367

10.  Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification.

Authors:  L J Schurgers; H M H Spronk; J N Skepper; T M Hackeng; C M Shanahan; C Vermeer; P L Weissberg; D Proudfoot
Journal:  J Thromb Haemost       Date:  2007-09-10       Impact factor: 5.824

View more
  14 in total

1.  JAK2/STAT3/BMP-2 axis and NF-κB pathway are involved in erythropoietin-induced calcification in rat vascular smooth muscle cells.

Authors:  Jin He; Xiaoyi Zhong; Lin Zhao; Hua Gan
Journal:  Clin Exp Nephrol       Date:  2018-11-07       Impact factor: 2.801

Review 2.  Angiotensin II and vascular injury.

Authors:  Augusto C Montezano; Aurelie Nguyen Dinh Cat; Francisco J Rios; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

Review 3.  Arterial Stiffness: A Nexus between Cardiac and Renal Disease.

Authors:  Guanghong Jia; Annayya R Aroor; James R Sowers
Journal:  Cardiorenal Med       Date:  2014-03-14       Impact factor: 2.041

4.  Matrix Gla protein (MGP) promoter polymorphic variants and its serum level in stenosis of coronary artery.

Authors:  Mohammad Najafi; Abazar Roustazadeh; Abdollah Amirfarhangi; Bahram Kazemi
Journal:  Mol Biol Rep       Date:  2014-01-21       Impact factor: 2.316

5.  Circulating Vitamin K Is Inversely Associated with Incident Cardiovascular Disease Risk among Those Treated for Hypertension in the Health, Aging, and Body Composition Study (Health ABC).

Authors:  M Kyla Shea; Sarah L Booth; Daniel E Weiner; Tina E Brinkley; Alka M Kanaya; Rachel A Murphy; Eleanor M Simonsick; Christina L Wassel; Cees Vermeer; Stephen B Kritchevsky
Journal:  J Nutr       Date:  2017-03-29       Impact factor: 4.798

6.  MicroRNA in cardiovascular calcification: focus on targets and extracellular vesicle delivery mechanisms.

Authors:  Claudia Goettsch; Joshua D Hutcheson; Elena Aikawa
Journal:  Circ Res       Date:  2013-03-29       Impact factor: 17.367

7.  Association between circulating vitamin K1 and coronary calcium progression in community-dwelling adults: the Multi-Ethnic Study of Atherosclerosis.

Authors:  M Kyla Shea; Sarah L Booth; Michael E Miller; Gregory L Burke; Haiying Chen; Mary Cushman; Russell P Tracy; Stephen B Kritchevsky
Journal:  Am J Clin Nutr       Date:  2013-05-29       Impact factor: 7.045

8.  Cortistatin exerts antiproliferation and antimigration effects in vascular smooth muscle cells stimulated by Ang II through suppressing ERK1/2, p38 MAPK, JNK and ERK5 signaling pathways.

Authors:  Ying Wang; Xin Zhang; Lei Gao; Jihe Li; Wenjia Chen; Jinyu Chi; Xiaohui Zhang; Yu Fu; Meng Zhao; Na Liu; Yang Li; Yang Xu; Kelaier Yang; Xinhua Yin; Yue Liu
Journal:  Ann Transl Med       Date:  2019-10

9.  Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein.

Authors:  Sophie Liabeuf; Olivier Bourron; Bourron Olivier; Cees Vemeer; Elke Theuwissen; Elke Magdeleyns; Carole Elodie Aubert; Michel Brazier; Romuald Mentaverri; Agnes Hartemann; Ziad A Massy
Journal:  Cardiovasc Diabetol       Date:  2014-04-24       Impact factor: 9.951

10.  Vascular calcification is coupled with phenotypic conversion of vascular smooth muscle cells through Klf5-mediated transactivation of the Runx2 promoter.

Authors:  Jing Zhang; Bin Zheng; Pei-Pei Zhou; Ruo-Nan Zhang; Ming He; Zhan Yang; Jin-Kun Wen
Journal:  Biosci Rep       Date:  2014-11-04       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.